Press Releases

24.04.2017

- Clinically relevant subgroups benefit from the treatment with lefitolimod in this study - Results are indicative for the further development of lefitolimod in SCLC

22.03.2017

• Ongoing implementation of the new “Next Level” corporate strategy • Funding secured until the start of 2018 through capital measures • Lead product lefitolimod: significant milestones reached • Changes to Executive Board • Confident...

27.02.2017

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first combination data of its TLR9 agonists EnanDIM® with a checkpoint inhibitor.

17.02.2017

The biotechnology company MOLOGEN (ISIN DE0006637200; Frankfurter Stock Exchange Prime Standard: MGN) will present a poster with the title “Combination of TLR9 agonists EnanDIM with checkpoint inhibitors for cancer immunotherapy" at the 2017...

16.02.2017

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today that its partner, the Danish Aarhus University Hospital, presented new data on the TEACH study at the annual Conference on Retroviruses...

13.02.2017

Dr Matthias Baumann MD will join the Executive Board of biotechnology Company MOLOGEN AG (ISIN DE0006637200, Frankfurt Stock Exchange Prime Standard: MGN) as Chief Medical Officer (CMO) on 1 May 2017. Dr Baumann’s areas of responsibility within the...

23.01.2017

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first combination data of its TLR9 agonist lefitolimod with checkpoint inhibitors.

   

Displaying results 1 bis 7 von 8

Page 1

Page 2

next

   

Positive subgroup results IMPULSE study

Press Release
Presentation

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.